Abbvie Inc. launched the second pivotal Phase III trial of elagolix in endometriosis, moving Neurocrine Biosciences Inc. one step closer to key catalysts for its product development pipeline. The 24-week, multinational, randomized, double-blind, placebo-controlled study is almost identical in design to the initial Phase III, with both evaluating safety and efficacy in premenopausal women with moderate to severe pain associated with endometriosis.